Evaluation of the Application Value of Combined Detection of BTA, BTA stat, NMP22, and Survivin in the Diagnosis of Urothelial Carcinoma

Objective: To explore the diagnostic value of combined detection of bladder tumor antigen (BTA), bladder tumor antigen-associated test (BTA stat), nuclear matrix protein 22 (NMP22), and survivin in urothelial carcinoma. Methods: Sixty patients with urothelial carcinoma admitted from January 2024 to January 2025 were selected as the observation group for this study, and 60 healthy individuals were selected as the control group. BTA, BTA stat, NMP22, and survivin tests were performed on both groups, respectively. The test results were analyzed to evaluate the diagnostic value of combined detection. Results: The levels of BTA, BTA stat, NMP22, and survivin in the observation group were higher than those in the control group (P < 0.05). The specificity, sensitivity, and accuracy of combined detection of BTA, BTA stat, NMP22, and survivin were higher than those of single detection methods (P < 0.05). There were significant differences in the positive rates of BTA, BTA stat, NMP22, and survivin among patients with different tumor diameters, tumor numbers, pathological grades, clinical stages, and lymph node metastasis status (P < 0.05). Conclusion: In the diagnosis of urothelial carcinoma, the combined detection of BTA, BTA stat, NMP22, and survivin has high diagnostic value and can be promoted and applied in clinical diagnosis.